Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of HW252001 tablets, aimed at treating idiopathic pulmonary fibrosis [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Hubei Biopharmaceutical Industry Technology Research Institute Co., Ltd., has been granted a Clinical Trial Approval Notice for HW252001 tablets [1] - HW252001 is an oral small molecule new drug intended for the treatment of idiopathic pulmonary fibrosis [1]

人民财讯12月19日电，ST人福（600079）12月19日公告，公司全资子公司湖北生物医药产业技术研究 院有限公司近日收到国家药监局核准签发的HW252001片的《药物临床试验批准通知书》,同意开展用于 特发性肺纤维化适应症的临床试验。 ...